Are There Therapeutic Strategies Targeting LKB1-Deficient Cancers?
Several therapeutic strategies are being explored to target LKB1-deficient cancers. One approach is to develop drugs that can mimic or reactivate LKB1 function. Another strategy involves targeting metabolic vulnerabilities specific to LKB1-deficient cells, such as inhibiting compensatory pathways like glutaminolysis. Researchers are also investigating combination therapies that pair metabolic inhibitors with other treatments to enhance efficacy against LKB1-deficient tumors.
